Table 1 Baseline Demographics of Gout Patients Discontinuing Pegloticase

Age, Years, Mean (SD)

60.3 (14.7)

Male, n (%)

311 (82.9)

Race, n (%)

 White

235 (62.7)

 Black or African American

34 (9.1)

 Other or unknown

106 (28.3)

Ethnicity, n (%)

 Not Hispanic or Latino

243 (64.8)

 Hispanic or Latino

10 (2.7)

 Missing

122 (32.5)

BMI on or before the index date, kg/m²

 Mean (SD)

32.4 (8.7)

 Missing, n

15

Number of gout diagnosis codes, Mean (SD)

14.4 (12.1)

RxRisk (0–46), Mean (SD)

9.0 (4.1)

Tophi, n (%)

288 (76.8)

Medication use in the 15 months before pegloticase ^a

Allopurinol, n (%)

181 (71.0)

Febuxostat, n (%)

101 (39.6)

Probenecid, n (%)

16 (6.3)

Lesinurad, n (%)

9 (3.5)

None, n (%)

120 (32.0)

Medication use on or before pegloticase discontinuation

Glucocorticoids, n (%)

312 (83.2)

Colchicine

289 (77.1)

NSAIDs, n (%)

222 (59.2)

Opioids, n (%)

122 (32.5)

IMMs, n (%)

115 (30.7)

 Methotrexate, n (%)

93 (24.8)

 Leflunomide, n (%)

13 (3.5)

 Azathioprine, n (%)

16 (4.3)

 Mycophenolate, n (%)

9 (2.4)

Baseline laboratory values

SU, mg/dL ^b

 Mean (SD)

7.8 (2.7)

 Median (IQR)

8.4 (6.1, 9.8)

eGFR, mL/min/1.73m^{2 c}

 Mean (SD)

74.8 (27.8)

 Median (IQR)

74.5 (54.9, 97.0)

CRP, mg/L ^d

 Mean (SD)

16.1 (41.1)

 Median (IQR)

5.0 (2.0, 13.0)

ESR, mm/hr ^e

 Mean (SD)

25.0 (23.8)

 Median (IQR)

17.5 (8.0, 33.0)